Chaparro M, et al. - Researchers evaluated the short and long-term efficacy of vedolizumab in patients with inflammatory bowel disease (IBD). They defined effectiveness based on Harvey-Bradshaw index (HBI) in Crohn's disease (CD) and Partial Mayo Score (PMS) in ulcerative colitis (UC). Logistic regression analysis was used to identify variables associated with short-term remission (assessed at week 14) and the Kaplan-Meier method to evaluate the long-term durability of vedolizumab treatment. They noted that over 60% of IBD patients respond to vedolizumab. Treatment was discontinued by many patients over time. CD and disease burden were identifying impairing both short- and long-term response. In clinical practice, vedolizumab appeared to be safe.